Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Free Newsletter Sign Up

Lilly Climbs After Winning Approval for Key New Diabetes Drug

May 13, 2022, 7:53 PM

(Updates with details on shares and competitor.)

Eli Lilly & Co. erases earlier losses after winning regulatory approval for a closely-watched diabetes drug, Mounjaro, that will compete with Novo Nordisk’s Wegovy. Both drugs are tied to weight loss, though Lilly’s drug has shown an even larger impact in recent studies.

  • NOTE: Friday is Lilly’s ex-dividend date.
  • The US Food and Drug Administration said that the average person getting the highest dose of Lilly’s drug lost 12 more pounds than those getting Novo’s medicine; the average weight loss was also 29 pounds more than with insulin degludec and 27 pounds more ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.